People with certain types of leukemia and lymphoma that has returned after treatment now have a new drug therapy to try the us food and drug administration fda has approved idelalisib zydelig for people with relapsed chronic lymphocytic leukemia cll relapsed follicular b cell non hodgkin lymphoma and relapsed small lymphocytic lymphoma another type of non hodgkin lymphoma. Fda label information for this drug is available at dailymed use in cancer idelalisib is approved to be used alone or with other drugs to treat chronic lymphocytic leukemia cll that has recurred come back it is used with rituximab in patients who are able to be treated with rituximab alone non hodgkin lymphoma nhl that has recurred come back. Zydelig is indicated for the treatment of relapsed chronic lymphocytic leukemia cll in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other comorbidities relapsed follicular b cell non hodgkin lymphoma fl in patients who have received at least two prior systemic therapies. The first in class kinase inhibitor idelalisib zydelig gilead can now be used in the treatment of chronic lymphocytic leukemia cll and for 2 types of lymphoma in patients who have relapsed . Idelalisib is used in combination with rituximab to treat chronic lymphocytic leukemia cll this medicine is also used to treat follicular b cell non hodgkin lymphoma fl and small lymphocytic lymphoma sll in patients who have received at least two previous treatmentsidelalisib interferes with the growth of cancer cells which are eventually destroyed by the body
How it works:
1. Register a Free 1 month Trial Account.
2. Download as many books as you like ( Personal use )
3. No Commitment. Cancel anytime.
4. Join Over 100.000 Happy Readers.
5. That's it. What you waiting for? Sign Up and Get Your Books.